Cleanoze® Irrigation Device With Powder Preparation Versus Conventional Irrigation Method for Chronic Rhinitis

Sponsor
Khon Kaen University (Other)
Overall Status
Completed
CT.gov ID
NCT02763241
Collaborator
Farmaline Co.,Ltd., Thailand (Other)
115
1
2
24
4.8

Study Details

Study Description

Brief Summary

The investigators proposed that the Cleanoze® is superior to the traditional nasal saline irrigation in term of the ease of use which will resulting in a better quality of life of the participants. This study will compared the efficacy, adverse reactions, complications and ease of use of Cleanoze® comparing with normal saline solution

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.

The nasal saline irrigation is the common procedure for upper respiratory tract infection patients including chronic rhinitis. The physician usually order the normal saline with appropriate medication e.g. anti-histamines, nasal steroids and anti-biotics to treat this condition.

The investigators proposed that the Cleanoze® is superior to the traditional nasal saline irrigation in term of the ease of use which will resulting in a better quality of life of the participants. This study will compared the efficacy, adverse reactions, complications and ease of use of Cleanoze® comparing with normal saline solution.

Study Population: Any patients with chronic rhinitis (e.g. allergic rhinitis, vasomotor rhinitis) will be randomized to receive the study or control medication. The investigators will include the children 5 years and above which able to doing the lavage under the parents assistant or by them self.

Study Design: Phase III randomized controlled trial

Sample Size: Estimate from pilot study, the 71 patients per arm was estimated (142 participants totally).

Study Duration:
  • Duration of enrollment is 1 year.

  • The patients will be followed up to 1 months depend on the disease conditions.

  • The data analysis will take 3 additional months

  • The full report will complete after the data analysis within 3 months

  • The total of 1 year and 6 months period needed for this study.

Primary Objective: To compare the satisfaction of the patients using Cleanoze® versus conventional device

Secondary Objective(s):
  • The adherence to Cleanoze® device

  • The durability of the Cleanoze® device

  • The patient symptom score (VAS)

  • The SNOT-22 questionaire for evaluating the quality of life of the patients

Study Design

Study Type:
Interventional
Actual Enrollment :
115 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase III Randomized Open-label Clinical Trial Comparing Cleanoze® Irrigation Device With Powder Preparation Versus Conventional Irrigation Method for Chronic Rhinitis
Actual Study Start Date :
Jan 1, 2016
Actual Primary Completion Date :
Jan 1, 2018
Actual Study Completion Date :
Jan 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cleanoze®

Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution. The patient will be instructed to use this isotonic solution for nasal irrigation daily.

Drug: Cleanoze®
Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.

Active Comparator: Syringe irrigation

Nasal irrigation using sterile 0.9% NaCl 250 ml by 20 ml syringe The patient will be instructed to use this isotonic solution for nasal irrigation daily.

Drug: Saline (Syringe irrigation)
Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe

Outcome Measures

Primary Outcome Measures

  1. Satisfaction score [1 month]

    This score will be evaluated at the end of 1 month using using the satisfaction questionaire

Secondary Outcome Measures

  1. The adherence to Cleanoze® devic [1 month]

    The adherence will be evaluated by the diary that the investigator given to the participants

  2. The durability of the Cleanoze® device [1 month]

    The durability will be evaluated by inspecting the device at the end of 1 month period

  3. The symptoms score of the patients [1 month]

    The symptoms score will be evaluated using the one-question VAS scale

  4. The Sino-Nasal Outcome Test-22 Questionnaire (SNOT-22) score [1 month]

    The SNOT-22 score will be evaluated by using SNOT-22 questionnaire

  5. Adverse events [1 month]

    The adverse events will be recorded in the case record form at follow-up time

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Any patients with chronic rhinitis conditions regardless of any cause (e.g. allergic, irritant, infection)
Exclusion Criteria:
  • Acute or chronic rhinosinusitis

  • Acute nasopharyngitis (common cold)

  • Patients with a tendency to aspirate such as cerebrovascular accident, cranio-facial diseases.

  • Sinunasal, nasopharyngeal and skull base tumors

  • Age under 5 years old.

  • Cannot administer a saline irrigation under the assistant of a care giver.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Otolaryngology, Khonkaen University Muang Khonkaen Thailand 40002

Sponsors and Collaborators

  • Khon Kaen University
  • Farmaline Co.,Ltd., Thailand

Investigators

  • Principal Investigator: Patorn Piromchai, MD, MSc, Khon Kaen University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Patorn Piromchai, Assistance Professor, Khon Kaen University
ClinicalTrials.gov Identifier:
NCT02763241
Other Study ID Numbers:
  • HE581519
First Posted:
May 5, 2016
Last Update Posted:
Aug 9, 2018
Last Verified:
Aug 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Patorn Piromchai, Assistance Professor, Khon Kaen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 9, 2018